Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Refractory Prostate Cancer Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT02698176
What this trial is testing

A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)

Who this might be right for
NUT Midline Carcinoma (NMC)Triple Negative Breast Cancer (TNBC)Non-small Cell Lung Cancer (NSCLC)+1 more
Merck Sharp & Dohme LLC 13
Large-scale testing (Phase 3)WithdrawnNCT00691899
What this trial is testing

Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Who this might be right for
Prostate Cancer
Merck Sharp & Dohme LLC
Not applicableStudy completedNCT03563014
What this trial is testing

A Local Retrospective Observational Study to Evaluate the Treatment Patterns of mCRPC Patients in Belgium Treated With Radium-223

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Bayer 164
Testing effectiveness (Phase 2)UnknownNCT03356444
What this trial is testing

Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate

Who this might be right for
Prostate CancerCastration-resistant Prostate CancerDrug
West China Hospital 140
Testing effectiveness (Phase 2)Looking for participantsNCT06145633
What this trial is testing

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Fred Hutchinson Cancer Center 15
Large-scale testing (Phase 3)WithdrawnNCT00043212
What this trial is testing

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Who this might be right for
Prostate Cancer
Northwest Biotherapeutics
Not applicableUnknownNCT04746300
What this trial is testing

ImPlementing ROutine Molecular Characterization in Patients With Metastatic Castration Resistant ProstaTe Cancer by NGS

Who this might be right for
Metastatic Prostate Cancer
Radboud University Medical Center 400
Early research (Phase 1)UnknownNCT00005992
What this trial is testing

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Who this might be right for
Prostate Cancer
Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)UnknownNCT05627752
What this trial is testing

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Who this might be right for
Prostate CancerCastrate Resistant Prostate Cancer
Zhongnan Hospital 120
Early research (Phase 1)Study completedNCT04786847
What this trial is testing

177Lu-DOTA-TLX591 Safety, Biodistribution and Dosimetry Study

Who this might be right for
Metastatic Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 30
Testing effectiveness (Phase 2)Study completedNCT00193232
What this trial is testing

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
SCRI Development Innovations, LLC 50
Very early researchStudy completedNCT06359821
What this trial is testing

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Sichuan University 4
Early research (Phase 1)Looking for participantsNCT03460977
What this trial is testing

Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)
Pfizer 453
Testing effectiveness (Phase 2)Study completedNCT00140400
What this trial is testing

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Cell Genesys 50
Testing effectiveness (Phase 2)Study completedNCT01867424
What this trial is testing

Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 24
Early research (Phase 1)Study completedNCT01144897
What this trial is testing

PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy

Who this might be right for
Castrate Resistant Prostate CancerProstate Cancer
Daniel Vaena 5
Large-scale testing (Phase 3)Study completedNCT01810770
What this trial is testing

Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis

Who this might be right for
Prostatic Neoplasms
Bayer 243
Testing effectiveness (Phase 2)Study completedNCT01120470
What this trial is testing

OGX-427 in Castration Resistant Prostate Cancer Patients

Who this might be right for
Castration Resistant Prostate Cancer
British Columbia Cancer Agency 74
Large-scale testing (Phase 3)Ended earlyNCT01313273
What this trial is testing

Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients

Who this might be right for
Prostate Cancer
Ipsen 3
Not applicableNo Longer AvailableNCT01516762
What this trial is testing

Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Who this might be right for
Prostatic Neoplasms
Bayer
Next Page